Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Highest risk of the class: up to 22.5 percent weight loss
They were all large-scale trials involving 3,000 to 18,000 patients who were either at high risk of or having established ASCVD, with trial durations ranging from 15 to 60 months
Retatrutide (research code LY3437943) is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor
Tirzepatide demonstrates high bioavailability of approximately 80% when administered subcutaneously in the abdomen, thigh, or upper arm
US$ 29.69
US$ 28.58
US$ 26.26
US$ 28.51
